The high degree of tumour (genomic and phenotypic) heterogeneity influences patient’s response to therapy and hampers wide deployment of personalised medicine for cancer treatment. Thus, there is an imperative need for new technologies that can accurately detect tumour heterogeneity, allow for patient stratification and assist clinicians in providing the right diagnosis and treatment for the right patient. PREDICT’s mission is to address this huge unmet need.
Radiomics, a newly emerging field that uses high-throughput extraction of large amounts of features from radiographic images, can boost the field of personalised medicine. However, researchers that understand cancer biology, advanced imaging and big data analytics are virtually absent. Even more challenging is to translate the outcomes into actual clinical tools involving the patient.
PREDICT will train 15 highly promising researchers in the emerging field of Radiomics and Big data. PREDICT builds upon a strong consortium with 8 academic and 10 non-academic partners that are all pioneers in their respective field.
PREDICT will give rise to highly trained and promising researchers in the emerging field of Radiomics and Big data.